LTRN
Lantern Pharma Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.91
+1.87%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | — | — | — |
| Cost of Revenue | 3.9K | — | — | 174.8K | — |
| Gross Profit | (3.9K) | — | — | (174.8K) | — |
| Operating Expenses | |||||
| R&D Expense | 8.7M | 11.5M | 16.1M | 11.9M | 8.6B |
| SG&A Expense | 6.8M | 6.5M | 6.1M | 6.0M | 5.8B |
| General & Admin Expense | 6.8M | 6.5M | 6.1M | 6.0M | 5.8B |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | — | — | — | (174.8K) | — |
| Total Operating Expenses | 15.5M | 18.0M | 22.2M | 17.7M | 14.4B |
| Cost and Expenses | 15.5M | 18.0M | 22.2M | 17.9M | 14.4B |
| Operating Income (EBIT) | (15.5M) | (18.0M) | (22.2M) | (17.9M) | (14.4B) |
| Non-Operating | |||||
| Interest Income | 245.6K | 437.9K | 742.4K | 765.4K | 204.4M |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | 245.6K | 437.9K | 742.4K | 765.4K | 204.4M |
| Other Non-Op Income/Expense | (3.2M) | 859.1K | 1.4M | 1.9M | 172.8M |
| Non-Operating Income (excl Interest) | 3.2M | (859.1K) | (1.4M) | (1.9M) | (172.8M) |
| EBT (Pre-Tax Income) | (18.7M) | (17.1M) | (20.8M) | (16.0M) | (14.3B) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (18.7M) | (17.1M) | (20.8M) | (16.0M) | (14.3B) |
| Earnings from Cont. Ops | (18.7M) | (17.1M) | (20.8M) | (16.0M) | (14.3B) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (18.7M) | (17.1M) | (20.8M) | (16.0M) | (14.3B) |
| Per Share | |||||
| Basic EPS | ($1.62) | ($1.57) | ($1,930.92) | ($1.47) | ($1.31) |
| Diluted EPS | ($1.62) | ($1.57) | ($1,930.92) | ($1.47) | ($1.31) |
| Revenue Per Share | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Shares | |||||
| Basic Shares Outstanding | 12.4M | 10.9M | 10.8M | 10.8M | 10.9M |
| Diluted Shares Outstanding | 12.4M | 10.9M | 10.8M | 10.8M | 10.9M |
| Profitability Metrics | |||||
| EBITDA | (18.6M) | (17.1M) | (20.8M) | (15.8M) | (14.3B) |
| D&A | 15.8K | 17.3K | 17.3K | 174.8K | — |
| EBIT | (18.7M) | (17.1M) | (20.8M) | (16.0M) | (14.3B) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026